Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Endocrine
Published in: Endocrine 3/2019

01-12-2019 | Respiratory Microbiota | Original Article

Comprehensive relationships between gut microbiome and faecal metabolome in individuals with type 2 diabetes and its complications

Authors: Lijuan Zhao, Hongxiang Lou, Ying Peng, Shihong Chen, Yulong Zhang, Xiaobo Li

Published in: Endocrine | Issue 3/2019

Login to get access

Abstract

Purpose

As the treatment regimens such as metformin could confound the correlation between type 2 diabetes (T2D) and gut microbiome, we should revisit the relationship between gut microbiota and T2D patients who are not currently treated with metformin.

Methods

The study recruited 65 T2D patients: 49 with and 16 without diabetic complications, and 35 healthy controls. We sequenced the 16S rRNA V3-V4 region of gut microbiota and detected metabolites based on liquid chromatography mass spectrometry (LC/MS) and gas chromatography mass spectrometry (GC/MS) in faecal samples.

Results

The composition of both the gut microbiota and faecal metabolites changed significantly with T2D patients. The abundance of Proteobacteria and the ratio of Firmicutes/Bacteroidetes were higher in T2D patients than healthy subjects, and the short chain fatty acids (SCFAs), bile acids and lipids of T2D patients were significantly disordered. Moreover, the abundances of certain SCFA-producing bacteria (Lachnospiraceae and Ruminococcaceae etc.) were significantly increased in T2D patients, while the faecal SCFAs concentrations were significantly decreased. It’s suggested that the role of SCFA-producing bacteria was not simply to produce SCFAs. Then we identified 44 microbial modules to explore the correlations between the gut microbiota and metabolic traits. Specially, most modules including certain SCFA-producing bacteria were comprehensively correlated to body mass index, the levels of blood glucose, blood pressure, blood cholesterol and faecal bile acids and lipids.

Conclusions

Our study identified the relationships between the gut microbiota and faecal metabolites, and provided a resource for future studies to understand host–gut microbiota interactions in T2D.
Appendix
Available only for authorised users
Literature
1.
S.V. Lynch, O. Pedersen, The human intestinal microbiome in health and disease. New Engl. J. Med. 375, 2369–2379 (2016)PubMedCrossRef
2.
3.
K. Forslund, F. Hildebrand, T. Nielsen, G. Falony, E. Le Chatelier, S. Sunagawa, E. Prifti, S. Vieira-Silva, V. Gudmundsdottir, H. Krogh Pedersen, M. Arumugam, K. Kristiansen, A.Yvonne Voigt, H. Vestergaard, R. Hercog, P. Igor Costea, J. Roat Kultima, J. Li, T. Jørgensen, F. Levenez, J. Dore; H.I.T.c. Meta, H.Bjørn Nielsen, S. Brunak, J. Raes, T. Hansen, J. Wang, S.Dusko Ehrlich, P. Bork, O. Pedersen, Disentangling type 2 diabetes and metformin treatment signatures in the human gut microbiota. Nature 528, 262 (2015)PubMedPubMedCentralCrossRef
4.
H. Wu, E. Esteve, V. Tremaroli, M.T. Khan, R. Caesar, L. Manneras-Holm, M. Stahlman, L.M. Olsson, M. Serino, M. Planas-Felix, G. Xifra, J.M. Mercader, D. Torrents, R. Burcelin, W. Ricart, R. Perkins, J.M. Fernandez-Real, F. Backhed, Metformin alters the gut microbiome of individuals with treatment-naive type 2 diabetes, contributing to the therapeutic effects of the drug. Nat. Med. 23, 850–858 (2017)PubMedCrossRef
5.
E. Org, Y. Blum, S. Kasela, M. Mehrabian, J. Kuusisto, A.J. Kangas, P. Soininen, Z. Wang, M. Ala-Korpela, S.L. Hazen, M. Laakso, A.J. Lusis, Relationships between gut microbiota, plasma metabolites, and metabolic syndrome traits in the METSIM cohort. Genome Biol. 18, 70 (2017)PubMedPubMedCentralCrossRef
6.
F. Brial, A. Le Lay, M.E. Dumas, D. Gauguier, Implication of gut microbiota metabolites in cardiovascular and metabolic diseases. Cell Mol. Life Sci. 75(21), 3977–3990 (2018)PubMedPubMedCentralCrossRef
7.
E.E. Canfora, J.W. Jocken, E.E. Blaak, Short-chain fatty acids in control of body weight and insulin sensitivity. Nat. Rev. Endocrinol. 11, 577–591 (2015)PubMedCrossRef
8.
Z. Wang, E. Klipfell, B.J. Bennett, R. Koeth, B.S. Levison, B. Dugar, A.E. Feldstein, E.B. Britt, X. Fu, Y.M. Chung, Y. Wu, P. Schauer, J.D. Smith, H. Allayee, W.H. Tang, J.A. DiDonato, A.J. Lusis, S.L. Hazen, Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature 472, 57–63 (2011)PubMedPubMedCentralCrossRef
9.
H.K. Pedersen, V. Gudmundsdottir, H.B. Nielsen, T. Hyotylainen, T. Nielsen, B.A. Jensen, K. Forslund, F. Hildebrand, E. Prifti, G. Falony, E. Le Chatelier, F. Levenez, J. Dore, I. Mattila, D.R. Plichta, P. Poho, L.I. Hellgren, M. Arumugam, S. Sunagawa, S. Vieira-Silva, T. Jorgensen, J.B. Holm, K. Trost, H.I.T.C. Meta, K. Kristiansen, S. Brix, J. Raes, J. Wang, T. Hansen, P. Bork, S. Brunak, M. Oresic, S.D. Ehrlich, O. Pedersen, Human gut microbes impact host serum metabolome and insulin sensitivity. Nature 535, 376–381 (2016)PubMedCrossRef
10.
V.K. Ridaura, J.J. Faith, F.E. Rey, J. Cheng, A.E. Duncan, A.L. Kau, N.W. Griffin, V. Lombard, B. Henrissat, J.R. Bain, Gut microbiota from twins discordant for obesity modulate metabolism in mice. Science 341, 1241214 (2013)PubMedCrossRef
11.
D. Dodd, M.H. Spitzer, W. Van Treuren, B.D. Merrill, A.J. Hryckowian, S.K. Higginbottom, A. Le, T.M. Cowan, G.P. Nolan, M.A. Fischbach, J.L. Sonnenburg, A gut bacterial pathway metabolizes aromatic amino acids into nine circulating metabolites. Nature 551, 648–652 (2017)PubMedPubMedCentralCrossRef
12.
R. Liu, J. Hong, X. Xu, Q. Feng, D. Zhang, Y. Gu, J. Shi, S. Zhao, W. Liu, X. Wang, H. Xia, Z. Liu, B. Cui, P. Liang, L. Xi, J. Jin, X. Ying, X. Wang, X. Zhao, W. Li, H. Jia, Z. Lan, F. Li, R. Wang, Y. Sun, M. Yang, Y. Shen, Z. Jie, J. Li, X. Chen, H. Zhong, H. Xie, Y. Zhang, W. Gu, X. Deng, B. Shen, X. Xu, H. Yang, G. Xu, Y. Bi, S. Lai, J. Wang, L. Qi, L. Madsen, J. Wang, G. Ning, K. Kristiansen, W. Wang, Gut microbiome and serum metabolome alterations in obesity and after weight-loss intervention. Nat. Med 23, 859–868 (2017)PubMedCrossRef
13.
A. Koh, A. Molinaro, M. Stahlman, M.T. Khan, C. Schmidt, L. Manneras-Holm, H. Wu, A. Carreras, H. Jeong, L.E. Olofsson, P.O. Bergh, V. Gerdes, A. Hartstra, M. de Brauw, R. Perkins, M. Nieuwdorp, G. Bergstrom, F. Backhed, Microbially produced imidazole propionate impairs insulin signaling through mTORC1. Cell 175, 947–961 e917 (2018)PubMedCrossRef
14.
American diabetes association, Standards of medical care in diabetes–2014. Diabetes Care 37(Suppl 1), S14–S80 (2014)
15.
American diabetes association, Standards of medical care in diabetes–2011. Diabetes Care 34(Suppl 1), S11–S61 (2011)
16.
R.C. Edgar, Search and clustering orders of magnitude faster than BLAST. Bioinformatics 26, 2460–2461 (2010)PubMedCrossRef
17.
J.G. Caporaso, J. Kuczynski, J. Stombaugh, K. Bittinger, F.D. Bushman, E.K. Costello, N. Fierer, A.G. Peña, J.K. Goodrich, J.I. Gordon, G.A. Huttley, S.T. Kelley, D. Knights, J.E. Koenig, R.E. Ley, C.A. Lozupone, D. McDonald, B.D. Muegge, M. Pirrung, J. Reeder, J.R. Sevinsky, P.J. Turnbaugh, W.A. Walters, J. Widmann, T. Yatsunenko, J. Zaneveld, R. Knight, QIIME allows analysis of high-throughput community sequencing data. Nat. Methods 7, 335 (2010)PubMedPubMedCentralCrossRef
18.
19.
D. McDonald, M.N. Price, J. Goodrich, E.P. Nawrocki, T.Z. DeSantis, A. Probst, G.L. Andersen, R. Knight, P. Hugenholtz, An improved Greengenes taxonomy with explicit ranks for ecological and evolutionary analyses of bacteria and archaea. ISME J. 6, 610–618 (2012)PubMedCrossRef
20.
M.G. Langille, J. Zaneveld, J.G. Caporaso, D. McDonald, D. Knights, J.A. Reyes, J.C. Clemente, D.E. Burkepile, R.L. Vega Thurber, R. Knight, R.G. Beiko, C. Huttenhower, Predictive functional profiling of microbial communities using 16S rRNA marker gene sequences. Nat. Biotechnol. 31, 814–821 (2013)PubMedPubMedCentralCrossRef
21.
D.H. Parks, G.W. Tyson, P. Hugenholtz, R.G. Beiko, STAMP: statistical analysis of taxonomic and functional profiles. Bioinformatics 30, 3123–3124 (2014)PubMedPubMedCentralCrossRef
22.
Y. Li, Y. Peng, P. Ma, H. Yang, H. Xiong, M. Wang, C. Peng, P. Tu, X. Li, Antidepressant-like effects of cistanche tubulosa extract on chronic unpredictable stress rats through restoration of gut microbiota homeostasis. Front. Pharmacol. 9, 967 (2018)
23.
R. Wang, Y. Peng, H. Meng, X. Li, Protective effect of polysaccharides fractions from Sijunzi decoction in reserpine-induced spleen deficiency rats. RSC Adv. 6, 60657–60665 (2016)CrossRef
24.
H. Cao, H. Huang, W. Xu, D. Chen, J. Yu, J. Li, L. Li, Fecal metabolome profiling of liver cirrhosis and hepatocellular carcinoma patients by ultra performance liquid chromatography–mass spectrometry. Analytica Chim. Acta 691, 68–75 (2011)CrossRef
25.
H. Liu, X. Chen, X. Hu, H. Niu, R. Tian, H. Wang, H. Pang, L. Jiang, B. Qiu, X. Chen, Y. Zhang, Y. Ma, S. Tang, H. Li, S. Feng, S. Zhang, C. Zhang, Alterations in the gut microbiome and metabolism with coronary artery disease severity. Microbiome 7, 68 (2019)PubMedPubMedCentralCrossRef
26.
D.S. Wishart, Y.D. Feunang, A. Marcu, A.C. Guo, K. Liang, R. Vazquez-Fresno, T. Sajed, D. Johnson, C. Li, N. Karu, Z. Sayeeda, E. Lo, N. Assempour, M. Berjanskii, S. Singhal, D. Arndt, Y. Liang, H. Badran, J. Grant, A. Serra-Cayuela, Y. Liu, R. Mandal, V. Neveu, A. Pon, C. Knox, M. Wilson, C. Manach, A. Scalbert, HMDB 4.0: the human metabolome database for 2018. Nucleic Acids Res. 46, D608–D617 (2018)PubMedCrossRef
27.
M. Sud, E. Fahy, D. Cotter, A. Brown, E.A. Dennis, C.K. Glass, A.H. Merrill Jr., R.C. Murphy, C.R. Raetz, D.W. Russell, S. Subramaniam, LMSD: LIPID MAPS structure database. Nucleic Acids Res. 35, D527–D532 (2007)PubMedCrossRef
28.
C.A. Smith, G. O’Maille, E.J. Want, C. Qin, S.A. Trauger, T.R. Brandon, D.E. Custodio, R. Abagyan, G. Siuzdak, METLIN: a metabolite mass spectral database. Therapeutic Drug Monit. 27, 747–751 (2005)CrossRef
29.
T. Wu, G. Xie, Y. Ni, T. Liu, M. Yang, H. Wei, W. Jia, G. Ji, Serum metabolite signatures of type 2 diabetes mellitus complications. J. Proteome Res. 14, 447–456 (2015)PubMedCrossRef
30.
P. Langfelder, S. Horvath, WGCNA: an R package for weighted correlation network analysis. BMC Bioinforma. 9, 559 (2008)CrossRef
31.
P. Langfelder, B. Zhang, S. Horvath, Defining clusters from a hierarchical cluster tree: the dynamic tree cut package for R. Bioinformatics 24, 719–720 (2008)PubMedCrossRef
32.
J. Qin, Y. Li, Z. Cai, S. Li, J. Zhu, F. Zhang, S. Liang, W. Zhang, Y. Guan, D. Shen, Y. Peng, D. Zhang, Z. Jie, W. Wu, Y. Qin, W. Xue, J. Li, L. Han, D. Lu, P. Wu, Y. Dai, X. Sun, Z. Li, A. Tang, S. Zhong, X. Li, W. Chen, R. Xu, M. Wang, Q. Feng, M. Gong, J. Yu, Y. Zhang, M. Zhang, T. Hansen, G. Sanchez, J. Raes, G. Falony, S. Okuda, M. Almeida, E. LeChatelier, P. Renault, N. Pons, J.M. Batto, Z. Zhang, H. Chen, R. Yang, W. Zheng, S. Li, H. Yang, J. Wang, S.D. Ehrlich, R. Nielsen, O. Pedersen, K. Kristiansen, J. Wang, A metagenome-wide association study of gut microbiota in type 2 diabetes. Nature 490, 55–60 (2012)PubMedCrossRef
33.
F.H. Karlsson, V. Tremaroli, I. Nookaew, G. Bergstrom, C.J. Behre, B. Fagerberg, J. Nielsen, F. Backhed, Gut metagenome in European women with normal, impaired and diabetic glucose control. Nature 498, 99–103 (2013)PubMedCrossRef
34.
W. Feng, H. Ao, C. Peng, D. Yan, Gut microbiota, a new frontier to understand traditional Chinese medicines. Pharmacol. Res. 142, 176–191 (2019)PubMedCrossRef
35.
J. Fernandes, W. Su, S. Rahat-Rozenbloom, T.M. Wolever, E.M. Comelli, Adiposity, gut microbiota and faecal short chain fatty acids are linked in adult humans. Nutr. Diabetes 4, e121 (2014)PubMedPubMedCentralCrossRef
36.
J.A. Vogt, T.M. Wolever, Fecal acetate is inversely related to acetate absorption from the human rectum and distal colon. J. Nutr. 133, 3145–3148 (2003)PubMedCrossRef
37.
A.V. Hartstra, K.E. Bouter, F. Backhed, M. Nieuwdorp, Insights into the role of the microbiome in obesity and type 2 diabetes. Diabetes Care 38, 159–165 (2015)PubMedCrossRef
38.
I. Moreno-Indias, L. Sanchez-Alcoholado, E. Garcia-Fuentes, F. Cardona, M.I. Queipo-Ortuno, F.J. Tinahones, Insulin resistance is associated with specific gut microbiota in appendix samples from morbidly obese patients. Am. J. Transl. Res. 8, 5672–5684 (2016)PubMedPubMedCentral
39.
L. Sanchez-Alcoholado, D. Castellano-Castillo, L. Jordan-Martinez, I. Moreno-Indias, P. Cardila-Cruz, D. Elena, A.J. Munoz-Garcia, M.I. Queipo-Ortuno, M. Jimenez-Navarro, Role of gut microbiota on cardio-metabolic parameters and immunity in coronary artery disease patients with and without type-2 diabetes mellitus. Front Microbiol. 8, 1936 (2017)PubMedPubMedCentralCrossRef
40.
J.P. Furet, L.C. Kong, J. Tap, C. Poitou, A. Basdevant, J.L. Bouillot, D. Mariat, G. Corthier, J. Dore, C. Henegar, S. Rizkalla, K. Clement, Differential adaptation of human gut microbiota to bariatric surgery-induced weight loss: links with metabolic and low-grade inflammation markers. Diabetes 59, 3049–3057 (2010)PubMedPubMedCentralCrossRef
41.
J. Li, F. Zhao, Y. Wang, J. Chen, J. Tao, G. Tian, S. Wu, W. Liu, Q. Cui, B. Geng, W. Zhang, R. Weldon, K. Auguste, L. Yang, X. Liu, L. Chen, X. Yang, B. Zhu, J. Cai, Gut microbiota dysbiosis contributes to the development of hypertension. Microbiome 5, 14 (2017)PubMedPubMedCentralCrossRef
42.
Z. Jie, H. Xia, S.L. Zhong, Q. Feng, S. Li, S. Liang, H. Zhong, Z. Liu, Y. Gao, H. Zhao, D. Zhang, Z. Su, Z. Fang, Z. Lan, J. Li, L. Xiao, J. Li, R. Li, X. Li, F. Li, H. Ren, Y. Huang, Y. Peng, G. Li, B. Wen, B. Dong, J.Y. Chen, Q.S. Geng, Z.W. Zhang, H. Yang, J. Wang, J. Wang, X. Zhang, L. Madsen, S. Brix, G. Ning, X. Xu, X. Liu, Y. Hou, H. Jia, K. He, K. Kristiansen, The gut microbiome in atherosclerotic cardiovascular disease. Nat. Commun. 8, 845 (2017)PubMedPubMedCentralCrossRef
43.
K.H. Allin, V. Tremaroli, R. Caesar, B.A.H. Jensen, M.T.F. Damgaard, M.I. Bahl, T.R. Licht, T.H. Hansen, T. Nielsen, T.M. Dantoft, A. Linneberg, T. Jorgensen, H. Vestergaard, K. Kristiansen, P.W. Franks, I.-D. consortium, T. Hansen, F. Backhed, O. Pedersen, Aberrant intestinal microbiota in individuals with prediabetes. Diabetologia 61, 810–820 (2018)PubMedPubMedCentralCrossRef
44.
W.H. Tang, Z. Wang, X.S. Li, Y. Fan, D.S. Li, Y. Wu, S.L. Hazen, Increased trimethylamine n-oxide portends high mortality risk independent of glycemic control in patients with type 2 diabetes mellitus. Clin. Chem. 63, 297–306 (2017)PubMedCrossRef
45.
F.P. Martin, Y. Wang, N. Sprenger, I.K. Yap, T. Lundstedt, P. Lek, S. Rezzi, Z. Ramadan, P. van Bladeren, L.B. Fay, S. Kochhar, J.C. Lindon, E. Holmes, J.K. Nicholson, Probiotic modulation of symbiotic gut microbial-host metabolic interactions in a humanized microbiome mouse model. Mol. Syst. Biol. 4, 157 (2008)PubMedPubMedCentralCrossRef
46.
X.Z. Zhang, S.X. Zheng, Y.M. Hou, A. Non-Targeted, Liquid chromatographic-mass spectrometric metabolomics approach for association with coronary artery disease: an identification of biomarkers for depiction of underlying biological mechanisms. Med. Sci. Monit. Int. Med. J. Exp. Clin. Res. 23, 613–622 (2017)
47.
J.S. Escobar, B. Klotz, B.E. Valdes, G.M. Agudelo, The gut microbiota of Colombians differs from that of Americans, Europeans and Asians. BMC Microbiol. 14, 311 (2014)PubMedPubMedCentralCrossRef
48.
A. Wahlstrom, S.I. Sayin, H.U. Marschall, F. Backhed, Intestinal crosstalk between bile acids and microbiota and its impact on host metabolism. Cell Metab. 24, 41–50 (2016)PubMedCrossRef
49.
M.S. Trabelsi, M. Daoudi, J. Prawitt, S. Ducastel, V. Touche, S.I. Sayin, A. Perino, C.A. Brighton, Y. Sebti, J. Kluza, O. Briand, H. Dehondt, E. Vallez, E. Dorchies, G. Baud, V. Spinelli, N. Hennuyer, S. Caron, K. Bantubungi, R. Caiazzo, F. Reimann, P. Marchetti, P. Lefebvre, F. Backhed, F.M. Gribble, K. Schoonjans, F. Pattou, A. Tailleux, B. Staels, S. Lestavel, Farnesoid X receptor inhibits glucagon-like peptide-1 production by enteroendocrine L cells. Nat. Commun. 6, 7629 (2015)PubMedCrossRef
50.
C. Thomas, A. Gioiello, L. Noriega, A. Strehle, J. Oury, G. Rizzo, A. Macchiarulo, H. Yamamoto, C. Mataki, M. Pruzanski, R. Pellicciari, J. Auwerx, K. Schoonjans, TGR5-mediated bile acid sensing controls glucose homeostasis. Cell Metab. 10, 167–177 (2009)PubMedPubMedCentralCrossRef
51.
O. Chavez-Talavera, A. Tailleux, P. Lefebvre, B. Staels, Bile acid control of metabolism and inflammation in obesity, type 2 diabetes, dyslipidemia, and nonalcoholic fatty liver disease. Gastroenterology 152, 1679–1694 e1673 (2017)PubMedCrossRef
52.
S.A. Joyce, J. MacSharry, P.G. Casey, M. Kinsella, E.F. Murphy, F. Shanahan, C. Hill, C.G. Gahan, Regulation of host weight gain and lipid metabolism by bacterial bile acid modification in the gut. Proc. Natl. Acad. Sci. USA 111, 7421–7426 (2014)PubMedCrossRefPubMedCentral
53.
G. Kakiyama, W.M. Pandak, P.M. Gillevet, P.B. Hylemon, D.M. Heuman, K. Daita, H. Takei, A. Muto, H. Nittono, J.M. Ridlon, M.B. White, N.A. Noble, P. Monteith, M. Fuchs, L.R. Thacker, M. Sikaroodi, J.S. Bajaj, Modulation of the fecal bile acid profile by gut microbiota in cirrhosis. J. Hepatol. 58, 949–955 (2013)PubMedPubMedCentralCrossRef
54.
X. Zheng, F. Huang, A. Zhao, S. Lei, Y. Zhang, G. Xie, T. Chen, C. Qu, C. Rajani, B. Dong, D. Li, W. Jia, Bile acid is a significant host factor shaping the gut microbiome of diet-induced obese mice. BMC Biol. 15, 120 (2017)PubMedPubMedCentralCrossRef
55.
56.
F. Liu, Z. Ling, Y. Xiao, Q. Yang, B. Wang, L. Zheng, P. Jiang, L. Li, W. Wang, Alterations of urinary microbiota in type 2 diabetes mellitus with hypertension and/or hyperlipidemia. Front Physiol. 8, 126 (2017)PubMedPubMedCentral
57.
K. Makki, E.C. Deehan, J. Walter, F. Bäckhed, The Impact of Dietary Fiber on Gut Microbiota in Host Health and Disease. Cell Host Microbe 23, 705–715 (2018)PubMedCrossRef
58.
A.V. Hartstra, M. Nieuwdorp, H. Herrema, Interplay between gut microbiota, its metabolites and human metabolism: dissecting cause from consequence. Trends Food Sci. Technol. 57, 233–243 (2016)CrossRef
Metadata
Title
Comprehensive relationships between gut microbiome and faecal metabolome in individuals with type 2 diabetes and its complications
Authors
Lijuan Zhao
Hongxiang Lou
Ying Peng
Shihong Chen
Yulong Zhang
Xiaobo Li
Publication date
01-12-2019
Publisher
Springer US
Published in
Endocrine / Issue 3/2019
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-019-02103-8

Other articles of this Issue 3/2019

Endocrine 3/2019 Go to the issue

Original Article

Variants in MCT10 protein do not affect FT3 levels in athyreotic patients

Original Article

Is there a correlation between thyroiditis and thyroid cancer?

Original Article

The tendency of reduced periodontal destruction in acromegalic patients showing similar inflammatory status with periodontitis patients

Meta-Analysis

Histopathological diagnosis of appendiceal neuroendocrine neoplasms: when to perform a right hemicolectomy? A systematic review and meta-analysis

Original Article

Sleep disorders and cognitive dysfunction in acromegaly

Original Article

A nomogram for predicting the presence of germline mutations in pheochromocytomas and paragangliomas
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits